 Now, the World Health Organization on Tuesday stated that the R21 Matrix M Malaria Vexin given provisional approval by the National Agency for Food and Drug Administration and Control NAFTA still needs to undergo more trials. Nigeria became the second country in the world to approve the use of the Malaria Vexin developed by the University of Oxford and manufactured by the Serum Institute of India. However, WHO, country representative to Nigeria Dr Walter Moulambol restated the importance and efficacy of the RTSS vaccine adopted by countries like Ghana and Kenya. Moulambol, while speaking, during a media poll at the UN House in Abuja on Tuesday emphasized the need for proper policy funding and education in efforts to get Nigeria and Africa to zero malaria. After approves, provisionally approved, in this speech I mentioned RTSS Malaria Vexin. This is not the one we are talking about, the one that NAFTA gave provisional approval and this is also in a way understandable because to get full approval, you need approval from WHO and that particular vaccine is still being studied. WHO does not have the full complement of data and information to enable it to endorse it or recommend it for use and you've seen the same process during the COVID-19 when we started seeing a new vaccine coming up. There was a dossier that went to WHO with a group of experts to review the evidence before recommending so that we are at that stage.